KLEOPATRA meeting 3

24.10.2023, 14.00-17.00 CEST hybrid

Venue:

Bundeswehr Institute of Microbiology, Neuherbergstr. 11, 80937 München, Germany

https://teams.microsoft.com/l/meetupjoin/19%3ameeting_MmY4OTg2MzktNmJlZC00NDEzLThhYWEtNTFhNjEzMDA3MGI5%40thread.v2/0? context=%7b%22Tid%22%3a%222b71bef9-3b13-4432-b5f4-1f5ac2278d0c%22%2c%22Oid%22%3a%223ec24944-d0c7-4c35-b000-54a35c5fdfea%22%7d

14:00-14.30 Minutes from last meeting and ongoing admin Zuzanna Drulis-Kawa

WP progress/interaction with partners/elements for reporting

14:30-15:00 WP1. ONE HEALTH *K. pneumoniae* strains monitoring – BfR as WP leader, **Jens A.**

Hammerl and others

15:00-15:30 WP2. Elaboration of phage preparations – IMB as WP leader, Joachim J.

Bugert/MarinaBrettraeger and others

- 15:30-16:00WP3. Application of CDs in the phage-host interplay UWR as WP leader, GrażynaMajkowska-Skrobek/ Zuzanna Drulis-Kawa
- 16:00-16:30 WP4. In vivo (mouse model) evaluation of most top AB/phage/CD combinations SU

as WP leader, Regis Tournebize

16:30-17:00 Discussion and final remarks

KLEOPATRA work plan and timeline as Gantt chart		Project duration, months																
		Year 1					Year 2						Year 3					
Number	Task description	Q1	Q	2	Q3	Q	4	Q1	Q	2	Q3	Q4	1 0	1	Q2	C	3	Q4
WP 1	ONE HEALTH K. pneumoniae strains monitoring	UWR, BfR, HUJI																
1.1	KP from clinics - sample collection			Ш	Ш		Ш	Ш	Ш		Ш	Ш	Ш		Ш	Ш	Ш	Ш
1.2	KP prevalence in animal / environmental settings – samples collection	Ш	Ш		Ш		Ш	Ш	Ш		Ш	Ш			Ш	Ш	Ш	Ш
1.3	KP phenotypic and antibiotics sensitivity testing	Ш			Ш		Ш	Ш							Ш	Ш	Ш	\square
1.4	WGS analysis of KP isolates																Ш	
WP 2	Elaboration of phage preparations	UWR, KUL, IMB, BfR, HUJI, INVITRIS																
2.1	WGS analysis of phages			Ш	Ш										Ш		Ш	\square
2.2	phage serotype specificity/isolation of new phages	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ц						Ш	Ш	\square
2.3	purification and stability of phage products			Ш	Ш		Ш	Ш	Ш								\square	
WP 3	Application of CDs in the phage-host interplay	UWR, KUL, IMB, BfR, HUJI																
3.1	CDs detection and production as recombinant proteins	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш		Ш	Ш	Ш	Ш
3.2	application of CDs for novel protocols of K serotype detection	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш		Ш	Ш	Ш		Ш	Ш	Ш	Ш
3.3	application of CDs for novel phagogram protocols	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Ш		Ш	Ш	Ш	Ш
3.4	novel combinations of AB/phage/CD and resistance emergence analyses	Ш	Ш	Ш	Ш		Ш	Ш	Ш	Ш	Ш	Ш	Ш		Ш	Ш	Ш	Ш
3.5	WGS analysis of bacterial resistant variants from 3.4	Ш	Ш	Ш	Ш		Ш	Ш	Ш		Ш						Ш	Ш
WP 4	In vivo (mouse model) evaluation of most top AB/phage/CD combinations							U١	NR	, KI	UL,	SU						
4.1	LD50 inoculum evaluation in model of pneumonia				Π		Π	Π	Π		\prod					Π	Π	\prod
4.2	antibacterials activity testing in model of pneumonia		Π				Π		Π									\square
4.3	phenotypic and WGS analyses of bacterial resistant variants from 4.2	Ш	Π	Π	Π		Π	Π	Π	Π								
WP 5	The development of new mathematical models for optimisation of antimicrobial	KUL																
	combinations in treatment protocols and companion diagnostics	 									_	_	_		_	_	_	
5.1	mathematical model for phage-host interactions and phage cocktail design	111	++	₩	Ш	11										4	4	Ш
5.2	KLEOPATRA software for the rational design of AB/phage/CD combination	Ш	Ш	Ш	Ш	Ш	Ш	Ш	Щ	Ш	Ш	Ш				Ш	Ш	
WP6	Project management and dissemination	 						a	all p	part	tne	rs		_				
6.1	Project coordination	\square	\prod	\prod	\square		\square	1	11							44	44	+++
6.2	Data Management Plan		4	\parallel	11	11	11	1	11		11					₩	₩	#
6.3	Dissemination and Communication Plan		\parallel	\parallel	\prod		11									4	4	
6.4	External Advisory Board		#	\parallel	\parallel	#	11	11		\parallel	#	Щ			\parallel	#	#	++
6.5	Intellectual Property Management				11											\square	Ш	